Oncimmune Holdings CEO Martin Gouldstone joined Steve Darling from Proactive to provide an encouraging trading update on the company’s recent commercial progress. Over the last quarter, Oncimmune has continued its positive momentum, signing three new contracts valued at £0.34 million. These add to an impressive streak, bringing the total to eight contracts worth £2.14 million secured in just three months. Two of the latest agreements mark a significant expansion, as they involve new work areas for an existing top 10 global pharmaceutical client, highlighting Oncimmune's growing versatility and value to major industry players. The third contract leverages Oncimmune’s expertise in profiling Immunoglobulin type E (IgE) autoantibodies, further solidifying its relationship with another top-tier pharmaceutical partner. Though these contracts do not prompt an increase in the FY2025 revenue outlook, they strengthen Oncimmune’s position to meet market expectations. The company now has visibility of over 40% of its FY2025 revenue target of £6.9 million, supported by a robust, high-confidence pipeline. This ongoing success underscores Oncimmune’s expanding commercial traction and its position as a trusted partner to leading pharmaceutical companies worldwide. #proactiveinvestors #oncimmuneholdingsplc #aim #onc.l #AutoantibodyProfiling #PharmaContracts #BiotechNews #IgEInnovation #Immunology #AutoimmuneDisease #CancerResearch #PharmaIndustry #ProactiveInvestors #MedicalResearch #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews